A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Not Recruiting

Trial ID: NCT01209143

Purpose

This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced solid tumors who are refractory to treatment or for whom no standard therapy exists.

Official Title

A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Stanford Investigator(s)

Heather Wakelee
Heather Wakelee

Winston Chen and Phyllis Huang Professor

Sunil Arani Reddy
Sunil Arani Reddy

Clinical Associate Professor, Medicine - Oncology

Anne Lynn S. Chang, MD
Anne Lynn S. Chang, MD

Professor of Dermatology

A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine

Eligibility


Inclusion Criteria:

   - Histologic documentation of incurable, locally advanced, or metastatic solid
   malignancy that has failed to respond to at least one prior regimen or for which there
   is no standard therapy

   - Documented negative serum pregnancy test for women of childbearing potential and use
   of two forms of contraception. Contraception must be used while the patient is
   enrolled in the study and for 12 months after the patient discontinues from the study.

   - For men with female partners of childbearing potential, agreement to use a latex
   condom and to advise their female partner to use an additional method of contraception
   during the study and for 3 months after their last dose of GDC-0449.

   - Agreement not to donate blood or blood products during the study and for at least 12
   months after their last dose of GDC-0449

   - For male patients, agreement not to donate sperm during the study and for at least 3
   months after their last dose of GDC-0449

   - Adequate hematopoietic capacity

   - Adequate renal function

   - Adequate hepatic function

   - At least 3 weeks since the patient's last chemotherapy, investigational agent,
   radiation therapy, or major surgical procedure and recovery to pre-treatment baseline
   or stabilization of all treatment-related toxicities

Exclusion Criteria:

   - Active infection requiring intravenous (IV) antibiotics

   - Clinically important history of liver disease significantly impairing hepatic
   function, including active viral or other hepatitis, current alcohol abuse, or
   cirrhosis

   - Any medical condition or diagnosis that would likely impair absorption of an orally
   administered drug

   - Pregnant or lactating

   - Treatment with excluded medications, including strong CYP450 inhibitors and inducers,
   within 2 weeks of study entry

   - Male patients already receiving rosiglitazone

   - Male patients with a known contraindication to rosiglitazone

   - Female patients already receiving oral contraception < 14 days prior to Day 1

   - Female patients with known contraindication to oral contraceptions

Intervention(s):

drug: rosiglitazone

drug: Vismodegib

drug: Norethindrone/ethinyl estradiol

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.